Prostate Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Causes of Death Unrelated to Prostate Cancer in the United States: 16-Year Cohort Study
Does Exercise Reduce PSA Levels and Growth of Localized Prostate Cancer?
Racial Disparities in Prostate Cancer Treatment During the COVID-19 Pandemic
Nonmetastatic Castration-Resistant Prostate Cancer: Benefits/Risks of Second-Generation AR Inhibitors in Older Men
Bone Resorption Inhibitors: Are They of Benefit to Patients Being Treated for Metastatic Prostate Cancer?
Does Early Initiation of ADT Improve Outcomes in Biochemically Recurrent Prostate Cancer?
Radiation Escalation and Short-Term Androgen Suppression in Prostate Cancer
Comparing Biopsy Methods for Detecting Clinically Significant Prostate Cancer
Predicting Outcomes With LuPSMA in Metastatic Castration-Resistant Prostate Cancer
Treating Low- to Intermediate-Risk Prostate Cancer With Targeted Focal Microwave Ablation
Can Genomic and Molecular Classifiers Impact Apalutamide Treatment in Prostate Cancer?
Transcriptional Profiles From Liquid Biopsy: A Prognostic Marker in Metastatic Prostate Cancer?
FDA Guidance for Using Metastasis-Free Survival as a Prostate Cancer Trial Endpoint
Radium-223 Plus Abiraterone or Enzalutamide: Real-World Look at Survival in Prostate Cancer
Dual Pathway Inhibition Under Study in Metastatic Castration-Resistant Prostate Cancer
Do Common Prostate Cancer Treatments Cause Cognitive Decline?
EAU21: Active Surveillance Versus Treatment for Older Men With Low-Risk Prostate Cancer
Comparing Imaging Modalities After Prostatectomy to Guide Radiotherapy Decision-Making
Phase II Study of Bipolar Androgen Therapy and Nivolumab in Prostate Cancer
Early Results With PSMA-Targeting T-Cell Engager in Metastatic Prostate Cancer
ASCO 2021: Prostate Cancer Treatment Disparities During First Wave of COVID-19 Pandemic
ASCO 2021: Bone-Protecting Agents With Enzalutamide Treatment for Metastatic Prostate Cancer
FDA Brief: Radioligand Therapy Receives Breakthrough Therapy Designation in Prostate Cancer
Long-Terms Results With Apalutamide Plus ADT in Metastatic Prostate Cancer
ASCO 2021: Early-Phase Study of Alpha Emitter in Castration-Resistant Prostate Cancer
ASCO 2021: ADT Plus Novel Targeted Therapy in Metastatic Prostate Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.